CRON
Price
$2.50
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
966.06M
60 days until earnings call
TLRY
Price
$1.19
Change
+$0.04 (+3.48%)
Updated
Sep 5 closing price
Capitalization
1.31B
26 days until earnings call
Interact to see
Advertisement

CRON vs TLRY

Header iconCRON vs TLRY Comparison
Open Charts CRON vs TLRYBanner chart's image
Cronos Group
Price$2.50
Change-$0.00 (-0.00%)
Volume$1.97M
Capitalization966.06M
Tilray Brands
Price$1.19
Change+$0.04 (+3.48%)
Volume$41.19M
Capitalization1.31B
CRON vs TLRY Comparison Chart in %
Loading...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRON vs. TLRY commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CRON: $2.50 vs. TLRY: $1.19)
Brand notoriety: CRON: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRON: 73% vs. TLRY: 61%
Market capitalization -- CRON: $966.06M vs. TLRY: $1.31B
CRON [@Pharmaceuticals: Generic] is valued at $966.06M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.31B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRON’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • CRON’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, CRON is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRON’s TA Score shows that 3 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • CRON’s TA Score: 3 bullish, 6 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than CRON.

Price Growth

CRON (@Pharmaceuticals: Generic) experienced а -3.85% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -13.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

CRON is expected to report earnings on Nov 05, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.31B) has a higher market cap than CRON($966M). CRON YTD gains are higher at: 23.762 vs. TLRY (-10.526). CRON has higher annual earnings (EBITDA): -25.58M vs. TLRY (-2.13B). CRON has more cash in the bank: 834M vs. TLRY (256M). CRON has less debt than TLRY: CRON (2.01M) vs TLRY (329M). TLRY has higher revenues than CRON: TLRY (821M) vs CRON (130M).
CRONTLRYCRON / TLRY
Capitalization966M1.31B74%
EBITDA-25.58M-2.13B1%
Gain YTD23.762-10.526-226%
P/E Ratio50.00N/A-
Revenue130M821M16%
Total Cash834M256M326%
Total Debt2.01M329M1%
FUNDAMENTALS RATINGS
CRON vs TLRY: Fundamental Ratings
CRON
TLRY
OUTLOOK RATING
1..100
1482
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9199
PRICE GROWTH RATING
1..100
4135
P/E GROWTH RATING
1..100
694
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (52) in the Biotechnology industry is in the same range as CRON (68) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as TLRY (99) in the Biotechnology industry. This means that CRON’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as CRON (41) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to CRON’s over the last 12 months.

CRON's P/E Growth Rating (6) in the Pharmaceuticals Other industry is significantly better than the same rating for TLRY (94) in the Biotechnology industry. This means that CRON’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRONTLRY
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
71%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYHIX128.161.17
+0.92%
Rydex Health Care Inv
CSCIX14.340.12
+0.84%
Cohen & Steers Real Estate Securities C
ACMTX10.51N/A
N/A
AB All Market Real Return C
ILGGX23.86N/A
N/A
Columbia Integrated Large Cap Gr Instl
NBSTX53.10-0.34
-0.64%
Neuberger Berman Quality Equity Tr

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been loosely correlated with TLRY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRON jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
N/A
TLRY - CRON
61%
Loosely correlated
+3.48%
OGI - CRON
58%
Loosely correlated
+2.48%
CGC - CRON
57%
Loosely correlated
+5.80%
ACB - CRON
55%
Loosely correlated
+1.66%
EBS - CRON
29%
Poorly correlated
-0.66%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been loosely correlated with CGC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if TLRY jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+3.48%
CGC - TLRY
63%
Loosely correlated
+5.80%
CRON - TLRY
61%
Loosely correlated
N/A
OGI - TLRY
60%
Loosely correlated
+2.48%
ACB - TLRY
56%
Loosely correlated
+1.66%
ELAN - TLRY
32%
Poorly correlated
+5.50%
More